Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib

BACKGROUND: This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib. METHODS: Patients received oral dovitinib 500 mg day(−1), 5 d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Joensuu, Heikki, Blay, Jean-Yves, Comandone, Alessandro, Martin-Broto, Javier, Fumagalli, Elena, Grignani, Giovanni, Del Muro, Xavier Garcia, Adenis, Antoine, Valverde, Claudia, Pousa, Antonio Lopez, Bouché, Olivier, Italiano, Antoine, Bauer, Sebastian, Barone, Carlo, Weiss, Claudia, Crippa, Stefania, Camozzi, Maura, Castellana, Ramon, Le Cesne, Axel
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5672922/
https://ncbi.nlm.nih.gov/pubmed/28850565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.290
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados